Furthermore, the more frequent combination use of anti-CD38 mAbs, in particular with IMiDs, is likely to trigger a powerful response of all the immune competent apparatus against Myeloma cells with unexpected results, thus paving the way for a putative cure of the disease. The gene discussed is CD38; the disease is plasma cell myeloma.